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Health policy
Applying clinical epidemiological methods to health
equity: the equity effectiveness loop
Peter Tugwell, Don de Savigny, Gillian Hawker, Vivian Robinson
Focusing on the average effects of interventions on health may miss important differences within
populations. Examining these effects across gradients in wealth allows the identification of the
interventions most likely to reduce health inequalities
Introduction
The world achieved impressive health gains during the
20th century.1 However, health worldwide is distributed
unevenly, according to socioeconomic status.2–4 Unfair
and avoidable health inequalities have been termed
health inequities.5 Modern health policy must ensure
that poor people are included in the benefits of
development.6
Objective
We propose the “equity effectiveness loop” framework
(fig 1) to highlight equity issues inherent in assessing
health needs, effectiveness, and cost effectiveness of
interventions, and the development and evaluation of
evidence based health policy. This framework provides
a method to calculate the “equity effectiveness ratio,”
which assesses the impact of various factors on the
gap in the effectiveness of interventions across socio-
economic gradients. Although we illustrate the
application of this approach when data are available
on the economic gradient across individuals, if social-
group attributes are also known, the approach could
be applied for other equity factors as illustrated by
the PROGRESS concept: place of residence; race,
ethnicity, and culture; occupation; sex; religion;
education; socioeconomic status; and social capital,
which reflects categories across which disadvantage
may exist.7 Including equity issues is an improvement
on the iterative measurement loop, which focused on
averages and thus ignored the distribution of health
effects.8 9
Information on the distribution of both “risk” and
“response” across the wealth gradient is critical for going
beyond mere measurement to designing strategies to
reduce the health gap between rich and poor.
Methods
This equity effectiveness loop provides a framework for
developing and evaluating population health interven-
tions and policies that explicitly focus on narrowing
the gap between rich and poor, using the best available
evidence. This framework integrates the concepts of
individual risk and socioeconomic status with inter-
vention effectiveness from a population health
perspective.
We will illustrate this framework with two interven-
tions: nets treated with insecticide for malaria
prevention (an acute infectious disease in low income
1. Burden of illness and aetiology
Determine health status by
socioeconomic status:
Measure health gap
Causes of health gap
Step 6: Reassessment
2. Equity effectiveness
Efficacy modified by access/
coverage x diagnostic accuracy
x provider and patient adherence
by socioeconomic status
5. Monitoring of programme
Ongoing monitoring of process
indicators to gauge implementation
progress by socioeconomic status
3. Economic evaluation
Determine relationships between
costs and effects of options by
socioeconomic status
4. Knowledge translation and
implementation
Integration of feasibility, impact,
and efficiency to make
decisions using targeted
packaging and communication
by socioeconomic status
Fig 1 Equity effectiveness loop
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countries), and total joint arthroplasty for osteoarthri-
tis (a chronic disease in industrialised countries). For
malaria, we compare the poorest and least poor across
all steps, since “richest” is not appropriate in
low-income country settings. For osteoarthritis, we
compare richest and poorest.
Results—step by step through the equity
effectiveness loop
Step 1: Burden of illness
This step measures the burden of illness and its gradi-
ent by socioeconomic status. This includes downstream
(individual), and upstream (societal) determinants of
health (psychosocial, biological, cultural, political, and
environmental).4–5 10–12
Malaria—Although malaria is preventable, control-
lable, and curable, more than 300 million cases are
reported each year. Malaria compounds poverty and
impedes economic development.13 Although the risk
of malarial fever varies little across socioeconomic
quintiles,14 an important gradient between least poor
and poorest quintiles is present in the risk of adverse
outcomes (fig 2).15
Osteoarthritis—Osteoarthritis is the fourth highest
cause of global morbidity16 and a leading cause of lost
productivity at work and decreased quality of life.17 18 A
significant socioeconomic gradient is present in
osteoarthritis even after adjusting for lifestyle risk
factors (fig 3).19–22
Step 2: Differential equity effectiveness
Controlled studies provide estimates of efficacy—that
is, how well an intervention can work in ideal
circumstances.23 Community effectiveness measures
how well an intervention works in real settings and sys-
tems at the community level. Community effectiveness
is often substantially lower than efficacy because of a
staircase effect (fig 4). This staircase effect is the result
of lower awareness, access, or coverage; screening,
diagnosis, or targeting; compliance of providers; and
adherence of consumers. Poor people probably have a
greater reduction in efficacy at all four steps and there-
fore a greater staircase effect than the least poor
people.We need to assess equity issues across each step
to identify barriers to implementation related to gradi-
ents in wealth. The table illustrates stepwise reductions
in efficacy that are greater in the poorest subpopula-
tions. This staircase effect therefore disadvantages
people who are already disadvantaged.
We use a simple, multiplicative model to estimate
community effectiveness in the table. This model
assumes that individual factors are not highly
correlated (even with optimal diagnosis, a patient’s
adherence may be low). By using this model, efficacy is
multiplied by the factors of access, diagnostic accuracy,
compliance of providers, and adherence of consumers
for the poorest and the least poor. We then calculate
the equity effectiveness ratio of the least poor to the
poorest. Access, diagnostic accuracy, compliance, and
adherence are based on composite data from a variety
of studies, with some guesswork based on clinical expe-
rience where data are lacking. The table aims to
illustrate the potential of this framework to illuminate
specific barriers related to wealth to implementation
and effectiveness across the gradient between least
poor (or richest) and poorest. The conclusions are not
to be taken as empirical. This framework estimates real
effectiveness of interventions in least poor (or richest)
and poorest subpopulations and highlights those areas
that, if improved, could have the greatest impact on
improving the effectiveness of interventions for the
poor subpopulations.
Malaria
The relative efficacy of treated bed nets on childhood
mortality24 is unlikely to differ across socioeconomic
status since the risk of malaria is similar across
socioeconomic gradients in areas of comparable ende-
micity. However, the absolute difference may be greater
in the poorest people, who start with higher baseline
mortality.24 25
We estimate hypothetical access on the assumption
of achieving theWorld Health Organization’s targets of
60% coverage by 2005, with a coverage ratio for the
poorest to the least poor of 0.57, as seen in small scale
social marketing projects.26 Diagnostic accuracy in tar-
geting people in greatest need depends on providers’
knowledge and is likely to be high for least poor and
poorest people alike. The compliance of providers
depends on how bed nets are delivered. If nets are sold
compliance is higher for the least poor, but even when
bed nets are freely provided it remains high, even in the
poorest.27 Typical adherence of consumers in trials of
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Fig 2 Mortality under age 5 by wealth quintiles across a small rural
area in a setting where malaria is endemic54
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bed nets is around 70%.24 28 We have postulated greater
adherence in the poorest because of higher exposure to
nuisance biting mosquitoes and less adherence in the
least poor because of access to other mosquito
avoidance technologies (such as screened windows).
We calculated community effectiveness for a reduc-
tion in child mortality of 7.7% in the least poor and
5.6% in the poorest. This represents 39% and 28% of
the potential achievable efficacy of 20%.24 The least
poor achieve 1.4 times the impact of the poorest. This
framework and hypothetical data imply that access is
the major barrier to achieving optimal efficacy in this
scenario. Once access is addressed, other factors in the
staircase with large differences across socioeconomic
status would need to be addressed to optimise
effectiveness.
These conclusions are limited by guesswork for
access and adherence. Empirical studies by socio-
economic status are lacking and are required to deter-
mine which factors pose the major barrier to achieving
improved effectiveness and equity effectiveness.
Osteoarthritis
Disparities in the use of arthroplasty across income,
education, and race result from these same factors.
Controlled before-after studies have shown an efficacy
of 86% for improved quality of life after arthroplasty.
We define access as having a doctor who raises consid-
eration for arthroplasty. A survey of 1105 people in
Ontario who were eligible for arthroplasty found that
83.3% of the richest and 75.8% of the poorest were
receiving care from a doctor for their arthritis.29
Diagnostic accuracy refers to recognition of need for
arthroplasty by the patient’s doctor. We estimate
diagnostic accuracy at 50% in the least poor and 43%
in the poorest; this estimate is based on the proportion
of individuals from this same cohort whose arthritis
care provider had discussed arthroplasty as a treatment
option. Once a patient is referred to an orthopaedic
surgeon, we define the compliance of the provider as
the surgeon’s recognition of need and appropriate rec-
ommendation for surgery. Concerns that arthroplasty
is overused have been dispelled.30 We chose an estimate
of 98%, postulating that once a patient sees an
orthopaedic surgeon, he or she will receive surgery if
needed. We used the proportion “definitely or
probably willing” to consider arthroplasty from the
same cohort to estimate the adherence of consumers:
36% of the richest and 28% of the poorest.29
Multiplying these factors gives a community
effectiveness of only 14.7% and 7.7% in the richest and
poorest, respectively. The richest achieve 1.6 times
greater benefits from arthroplasty than the poorest.
Over 85% of the potential efficacy is lost in both rich and
poor, mainly because of poor access and adherence of
consumers. Interventions are urgently needed to tackle
perceived barriers and low willingness to undergo
arthroplasty. The barriers of access and adherence of
consumers are greater in the poorest groups.
Step 3: Economic evaluation
This step assesses the efficiency (health benefits (number
of disability adjusted life years avoided) obtained for a
specific cost (direct, indirect, and where possible intangi-
ble costs)) of the intervention. Assessing the efficiency
requires adequate evidence of efficacy and valid
estimates of cost. Assessing the equity issues related to
cost effectiveness implies a trade-off between cost
efficiency and population health equity. Priority funding
of interventions with the best cost effectiveness ratios
might increase differences between richest (or least
poor) and poorest because the cost of reaching poor
people may be higher and health benefits may be lower.
One promising method to assess equity issues related to
cost effectiveness is the development of an equity and
quality adjusted life year (EQ-QALY), as a complement
to established measures of the difference between rich
and poor, such as the concentration index.31 32
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Fig 4 Staircase effect of increasing gap and decreasing effectiveness
across four factors, illustrated by using hypothetical estimates for
total joint arthroplasty. As efficacy is multiplied by each of the four
modifiers of access, diagnostic accuracy, provider compliance, and
consumer adherence, the staircase effect causes decreasing
community effectiveness and increasing relative gap between poorest
and least poor from zero gap in “ideal” efficacy conditions to a ratio
of least poor to poorest in “real life” of 1.6 (shown in the table)
Ratios of poorest to least poor (or richest) subpopulations for community effectiveness: the differential “staircase” effect. Values are
percentages unless otherwise indicated
Efficacy
Modifiers of efficacy
Community
effectiveness
Least poor (richest):poorest
equity effectiveness ratioAccess
Diagnostic
accuracy
Provider
compliance
Consumer
adherence
Treated bed nets for under-five mortality due to malaria
Least poor 20 75 95 90 60 7.7 1.4
Poorest 20 43 95 80 85 5.6
Arthroplasty for disability due to osteoarthritis
Richest 86 83 50 98 36 12.6 1.6
Poorest 86 76 43 98 28 7.7
*Community effectiveness is the product of the efficacy modifiers of access, diagnostic accuracy, compliance of providers, and adherence of consumers.
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Malaria
Bed nets treated with insecticide are a simple, safe, and
cost effective method of protection against malaria.33
However, one of the reasons for the wealth gradient in
malaria prevention using bed nets is that the least poor
have greater purchasing power and access to informa-
tion and markets than poorer people—an important
issue for social marketing programmes.15 The degree
to which these wealth gradients persist or the pace at
which they are mitigated is a measure of the extent to
which these bed net strategies may benefit the poor.
Osteoarthritis
Despite the high cost of arthroplasty, studies have
shown very favourable cost effectiveness ratios.34–37 Cost
effectiveness by wealth gradients is not available.
Developing interventions to reach populations with
low income and low education might be more expen-
sive because of the need for increased intensity, multi-
faceted interventions, and appropriate reading level.
This will result in less favourable cost effectiveness
ratios, unless reducing the gap between rich and poor
is considered in assessing cost effectiveness, by using
methods such as the EQ-QALY described above.
Step 4: Knowledge translation and implementation
Translation of knowledge is defined as the process that
transfers research results from producers of knowledge
to its users, for the benefit of the population. Moving
beyond the traditional domain of academic publication,
it comprises three interlinked components of uptake
and translation: exchange, synthesis, and ethically sound
application of knowledge.38 This step entails uptake and
translation of knowledge into action.39–42
Therefore we must develop new, effective means of
packaging and communicating evidence on effective-
ness across wealth gradients to the different policy,
community, and practitioner groups or individuals
responsible for each of the components of community
effectiveness—access, diagnostic accuracy, compliance
of providers, and adherence of consumers.40 Evidence
that interventions using knowledge translation are effi-
cacious is currently lacking in most sectors.43–46 One
exception is the work of the International Clinical Epi-
demiology Network, which is developing methods
explicitly to consider equity issues in developing and
applying clinical guidelines.47 By targeting the wealth
gradient in knowledge translation strategies, we
support the operational research agenda for optimis-
ing the benefits to the poor of key interventions.
Malaria
Social marketing of treated bed nets is an active imple-
mentation strategy, including the identification of bar-
riers through extensive market research and public
opinion surveys, followed by professional and innova-
tive marketing strategies to tackle these barriers. Social
marketing increased coverage from 10% to 50% in
three years in Tanzania.48 Social marketing also helps
in closing the gap in coverage between the poorest and
the least poor over time.15 Other approaches may close
this gap faster.
Osteoarthritis
Disparities in the rate of arthroplasty use by socio-
economic gradients need to be dealt with. A patient’s
socioeconomic position, ethnicity, or sex may influence
the encounter between patient and doctor.49 50 Current
initiatives to educate the population about osteoarthri-
tis and indications for surgery and to develop culturally
sensitive decision support tools to elicit patients’
preferences for treatment need to take socioeconomic
position into account.
Steps 5 and 6: Monitoring and reassessment
Monitoring identifies the importance of process
assessments and intermediate outcomes to assess
success in affecting mortality and morbidity by
socioeconomic group and deciding whether further
remediable need exists; if so, an additional iteration of
the equity effectiveness loop is needed. The Whitehall
cohort study, for example, showed that even with equi-
table access to cardiac care, the social deprivation gra-
dient still produces disparities in outcomes,51 indicating
a need to tackle other causes of disparities.
International approaches to monitoring equity
may be useful for this step. The Global Equity Gauge
Alliance has developed “equity gauges” to track gaps in
health by assessing key indicators, involving the public
and advocacy.52 The Health Metrics Network will
enable performance based monitoring of interven-
tions and health systems, with a focus on equity issues,
to promote policy decisions based upon evidence.53
Discussion
For equity to be achieved, factors that are known to
lead to inequalities need to be reversed. This equity
effectiveness loop can provide a useful framework to
assess the barriers to reversing health inequities and to
use as a basis for implementing equity oriented change
and improved opportunities for health for disadvan-
taged populations. This might be used by groups and
agencies responsible for making decisions on access to
resources—for example, the National Institute for
Health and Clinical Excellence and the World Health
Organization—to ensure that equity issues are consid-
ered systematically.
This framework needs to be validated by empirical
studies to show how it could be used to design and tar-
get interventions to reduce the gradient in health in
effectiveness of interventions. Furthermore, because
the evidence still has gaps, we need to organise
available information systematically and identify the
potential gaps explicitly so that an informed decision
may be made, whether it be a recommendation for
funding, further study, or remedial action. The
Cochrane Collaboration Equity Field will assemble
evidence on these interventions.
Summary points
To reduce the gap in health between rich and poor, a strategic
approach is needed to designing and implementing interventions
and policies that are effective in low income settings
The “equity effectiveness loop” provides a way of checking that the
effects of interventions are examined across the gradients in wealth
By helping to determine which factors are likely to have the greatest
impact on reducing health inequalities the framework should
improve the targeting of interventions
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